IMPORTANT UPDATE
The Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) has gone into effect, as of 4/24/25, ending reimbursement for PancraGEN®.
Because PancraGEN is primarily ordered for Medicare patients, this means that Interpace Diagnostics can no longer offer PancraGEN and the related Point2® fluid chemistry tests for amylase, CEA, glucose.
Specimens and orders for PancraGEN and fluid chemistry testing received after May 2, 2025* will not be accepted for testing.
Please plan accordingly.
*The last shipping date using FedEx Priority Overnight would be Thursday, May 1st. (Ensure the FedEx pickup time cutoff is met)
ThyGeNEXT®+ThyraMIR®v2 testing for indeterminate thyroid nodules continues to remain available without interruption.
View Details
 |
